Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - montelukast sodium, quantity: 4.16 mg (equivalent: montelukast, qty 4 mg) - tablet, chewable - excipient ingredients: mannitol; hyprolose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; iron oxide red; aspartame; flavour - prophylaxis and treatment of chronic asthma in adults and children two years of age and older. symptomatic treatment of seasonal allergic rhinitis

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - montelukast sodium, quantity: 4.15 mg - tablet, chewable - excipient ingredients: mannitol; microcrystalline cellulose; hyprolose; croscarmellose sodium; iron oxide red; aspartame; magnesium stearate; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - montelukast (unii: mhm278sd3e) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - montelukast sodium chewable tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium chewable tablets are indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. sodium chewable tablets are indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 of age and older. because the benefits of montelukast sodium chewable tablets may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis , use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium chewable tablets are indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. because the ben

Australia - English - Department of Health (Therapeutic Goods Administration)

fair-med healthcare australia pty ltd - montelukast sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - montelukast sodium, quantity: 4.16 mg (equivalent: montelukast, qty 4 mg) - tablet, chewable - excipient ingredients: aspartame; magnesium stearate; microcrystalline cellulose; mannitol; croscarmellose sodium; iron oxide red; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية النور - noor drug store - montelukast as sodium 4 mg - as sodium 4 mg

United States - English - NLM (National Library of Medicine)

ajanta pharma usa inc. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - montelukast sodium tablets, chewable tablets and oral granules are indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. montelukast sodium tablets and chewable tablets are indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium tablets, chewable tablets and oral granules are indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. because the benefits of montelukast sodium tablets, chewable tablets and oral granules may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium tablets, chewable tablets and oral granules are not indicated for the treatment of an acute asth

United States - English - NLM (National Library of Medicine)

torrent pharmaceuticals limited - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older.  because the benefits of montelukast sodium may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium is not indicated for the treatment of an acute asthma attack. montelukast sodium is contraindicated in patients with hypersensitivity to any of its components. risk summary available  data  from  published  prospective  and  retrospective  cohort  studies  over

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 10 mg - montelukast sodium tablets and montelukast sodium chewable tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium tablets and montelukast sodium chewable tablets are indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium tablets and montelukast sodium chewable tablets are indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. because the benefits of montelukast sodium may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions ( 5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium tablets and montelukast sodium chewable tablets are not indicated for the treatment of an acute asthma attack. ris

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - montelukast sodium, quantity: 4.16 mg (equivalent: montelukast, qty 4 mg) - tablet, chewable - excipient ingredients: mannitol; microcrystalline cellulose; iron oxide red; aspartame; hyprolose; magnesium stearate; croscarmellose sodium; flavour - -prophylaxis and treatment of chronic asthma in children 2 years to 14 years of of age.,-symptomatic treatment of seasonal allergic rhinitis in children 2 years to 14 years of of age.